Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liriopein B is a naturally occurring homoisoflavonoid compound isolated from the roots of Liriope platyphylla, a plant used in traditional Chinese medicine. It has demonstrated moderate anticancer activity in vitro, primarily through inhibition of the PI3K/AKT signaling pathway by blocking AKT phosphorylation, and subsequent downstream inhibition of FoxO3a activity. This results in suppressed proliferation and promoted cell death of cancer cells. The compound has also shown activation effects on apoptosis- and autophagy-associated markers in cancer cells treated with related root extracts. Liriopein B is being investigated mainly for its potential as an anticancer (antineoplastic) agent targeting signaling kinases involved in cell growth and survival[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liriopein B.